Novel Function for Endothelial Protease-Activated Receptors in Modulating Insulin Receptor Activity With Implications for Diabetes
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.125.323140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Rahul Rajala und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation (R.R., C.T.G.). Hauptthemen laut MEDLINE: Receptor, PAR-1, Receptor, Insulin, Diabetes Mellitus, Experimental, Endothelial Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Thrombin, a serine protease with increased activity in people with diabetes, signals through PAR (protease-activated receptor) 1 and 4 on endothelial cells (ECs). On these cells, PAR1 is a high-expressing, high-affinity, low-potency thrombin receptor, whereas PAR4 is a low-expressing, low-affinity, high-potency receptor. This study aims to determine how endothelial PARs influence diabetic pathology, thereby providing deeper insights into the roles and relationships between these receptors. METHODS: We generated mice with inducible deletion of Par1/Par4 in ECs ( Par1/4 iECko ) and induced diabetes with streptozotocin treatment. Blood glucose and insulin levels were assessed after streptozotocin administration. In addition, we measured insulin and glucose tolerance in Par1/4 iECko mice. Lastly, we measured how the loss of endothelial PARs in cultured primary ECs affected IR (insulin receptor) activity/phosphorylation, and insulin transcytosis. RESULTS: While studying the roles of endothelial PAR1/4 in diabetic pathology, we found that Par1/4 iECko mice displayed increased insulin sensitivity and were protected against streptozotocin-induced diabetes. Concordantly, we found that cultured primary ECs with PAR1/4 deficiency exhibited increased basal activity and phosphorylation of IR in a Gα q /protein kinase C-dependent manner, as well as enhanced insulin transcytosis. This elevated IR activity correlated with reduced activity of PTP1B (protein tyrosine phosphatase 1B), a negative regulator of IR. Lastly, Par1/4 iECko mice with additional deletion of 1 allele of the endothelial IR gene demonstrated restoration of diabetic phenotypes after streptozotocin treatment, indicating that insulin sensitivity in Par1/4 iECko mice was driven by heightened IR activity in ECs. CONCLUSIONS: These findings establish a novel link between endothelial PAR signaling and insulin sensitivity, underscoring the critical role of ECs in metabolic homeostasis and identifying a potential therapeutic target for diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation (R.R., C.T.G.).
- Department of Cell Biology (R.R., C.T.G.), University of Oklahoma Health Sciences.
- Harold Hamm Diabetes Center (R.R.), University of Oklahoma Health Sciences.
- Now with College of Medicine, University of Oklahoma Health Sciences (R.R.).
ORCID-Profile: Rahul Rajala, Courtney T Griffin
Förderung
- NHLBI NIH HHS
Zitieren
APA
Rajala, R., & Griffin, C. T. (2025). Novel Function for Endothelial Protease-Activated Receptors in Modulating Insulin Receptor Activity With Implications for Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.125.323140
Vancouver
Rajala R, Griffin CT. Novel Function for Endothelial Protease-Activated Receptors in Modulating Insulin Receptor Activity With Implications for Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.125.323140
BibTeX
@article{Rajala2025,
author = {Rajala, Rahul and Griffin, Courtney T},
title = {Novel Function for Endothelial Protease-Activated Receptors in Modulating Insulin Receptor Activity With Implications for Diabetes},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.125.323140}
}
EUVIMED